Author

B. R. Daley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

N. E. Sealover· 3 shared R. L. Kortum· 3 shared A. J. Linke· 2 shared J. M. Hughes· 2 shared P. L. Theard· 2 shared A. Frank· 1 shared A. Linke· 1 shared B. Mair· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

N. E. Sealover

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 7, 2023

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

B. R. Daley, N. E. Sealover, E. Sheffels…·R. L. Kortum

This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.

DOI 10.1101/2023.12.07.570642

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivJan 27, 2023

In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies

N. E. Sealover, P. L. Theard, J. M. Hughes…·R. L. Kortum

This paper introduces an in situ resistance assay to model acquired resistance to RTK/RAS pathway targeted therapies and shows SHP2 inhibitors can delay resistance development.

DOI 10.1016/j.isci.2023.108711

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivJan 20, 2023

SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis

P. L. Theard, A. J. Linke, N. E. Sealover…·R. L. Kortum

This study shows SOS2 modulates EGFR-PI3K signaling threshold, affecting osimertinib efficacy and resistance in lung adenocarcinoma.

DOI 10.1002/1878-0261.13564

humanexperimental assay

𝕏 PostBluesky